Catherine A. Behrmann

Catherine A. Behrmann

Auto-generated profile, based on publicly available information

Catherine A. Behrmann

Department of Cancer Biology, University of Cincinnati College of Medicine, Cincinnati, Ohio

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2024 in Cancer Discovery
Verified
Journal Article
Open access
MBMegan E. Bischoff
Megan E. Bischoff
BSBehrouz Shamsaei
Behrouz Shamsaei
JYJuechen Yang
Juechen Yang
DSDina Secic
Dina Secic
BVBhargav Vemuri
Bhargav Vemuri
Maria F. Czyzyk-KrzeskaMaria F. Czyzyk-Krzeska
Maria F. Czyzyk-Krzeska
Copper (Cu) is a cofactor of cytochrome c oxidase (CuCOX), indispensable for aerobic mitochondrial respiration. This study reveals that advanced clear cell renal cell carcinomas (ccRCC) accumulate Cu, allocating it to CuCOX. Using a range of orthogonal approaches, including metabolomics, lipidomics, isotope-labeled glucose and glutamine flux analysis, and transcriptomics across tumor samples, cell lines, xenografts, and patient-derived xenograft models, combined with genetic and pharmacologic interventions, we explored the role of Cu in ccRCC. Elevated Cu levels stimulate CuCOX biogenesis, providing bioenergetic and biosynthetic benefits that promote tumor growth. This effect is complemented by glucose-dependent glutathione production, which facilitates detoxification and mitigates Cu–H2O2 toxicity. Single-cell RNA sequencing and spatial transcriptomics reveal increased oxidative metabolism, altered glutathione and Cu metabolism, and diminished hypoxia-inducible transcription factor activity during ccRCC progression. Thus, Cu drives an integrated oncogenic remodeling of bioenergetics, biosynthesis, and redox homeostasis, fueling ccRCC growth, which can be targeted for new therapeutic approaches. Significance: The work establishes a requirement for glucose-dependent coordination between energy production and redox homeostasis, which is fundamental for the survival of cancer cells that accumulate Cu and contributes to tumor growth.

1 August 2024 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
CBCatherine A. Behrmann
Catherine A. Behrmann
KEKelli N. Ennis
Kelli N. Ennis
PSPRANJAL SARMA
PRANJAL SARMA
CWCollin Wetzel
Collin Wetzel
NCNicholas A. Clark
Nicholas A. Clark
DPDavid R. Plas
David R. Plas
Intrinsic resistance to targeted therapeutics in PTEN-deficient glioblastoma (GBM) is mediated by redundant signaling networks that sustain critical metabolic functions. Here, we demonstrate that coordinated inhibition of the ribosomal protein S6 kinase 1 (S6K1) and the receptor tyrosine kinase AXL using LY-2584702 and BMS-777607 can overcome network redundancy to reduce GBM tumor growth. This combination of S6K1 and AXL inhibition suppressed glucose flux to pyrimidine biosynthesis. Genetic inactivation studies to map the signaling network indicated that both S6K1 and S6K2 transmit growth signals in PTEN-deficient GBM. Kinome-wide ATP binding analysis in inhibitor-treated cells revealed that LY-2584702 directly inhibited S6K1, and substrate phosphorylation studies showed that BMS-777607 inactivation of upstream AXL collaborated to reduce S6K2-mediated signal transduction. Thus, combination targeting of S6K1 and AXL provides a kinase-directed therapeutic approach that circumvents signal transduction redundancy to interrupt metabolic function and reduce growth of PTEN-deficient GBM. Significance: Therapy for glioblastoma would be advanced by incorporating molecularly targeted kinase-directed agents, similar to standard of care strategies in other tumor types. Here, we identify a kinase targeting approach to inhibit the metabolism and growth of glioblastoma.

17 June 2026
Verified
Other
Open access
MBMegan E. Bischoff
Megan E. Bischoff
BSBehrouz Shamsaei
Behrouz Shamsaei
JYJuechen Yang
Juechen Yang
DSDina Secic
Dina Secic
BVBhargav Vemuri
Bhargav Vemuri
Maria F. Czyzyk-KrzeskaMaria F. Czyzyk-Krzeska
Maria F. Czyzyk-Krzeska
Characterization of subpopulations of cancer cells identified by scRNA-seq.

17 June 2026
Verified
Other
Open access
MBMegan E. Bischoff
Megan E. Bischoff
BSBehrouz Shamsaei
Behrouz Shamsaei
JYJuechen Yang
Juechen Yang
DSDina Secic
Dina Secic
BVBhargav Vemuri
Bhargav Vemuri
Maria F. Czyzyk-KrzeskaMaria F. Czyzyk-Krzeska
Maria F. Czyzyk-Krzeska
Differential gene expression in tumors from S3DF and S3RL patients.

17 June 2026
Verified
Other
Open access
MBMegan E. Bischoff
Megan E. Bischoff
BSBehrouz Shamsaei
Behrouz Shamsaei
JYJuechen Yang
Juechen Yang
DSDina Secic
Dina Secic
BVBhargav Vemuri
Bhargav Vemuri
Maria F. Czyzyk-KrzeskaMaria F. Czyzyk-Krzeska
Maria F. Czyzyk-Krzeska
Steady-state metabolomics in CuHi and CuLo cells.

17 June 2026
Verified
Other
Open access
MBMegan E. Bischoff
Megan E. Bischoff
BSBehrouz Shamsaei
Behrouz Shamsaei
JYJuechen Yang
Juechen Yang
DSDina Secic
Dina Secic
BVBhargav Vemuri
Bhargav Vemuri
Maria F. Czyzyk-KrzeskaMaria F. Czyzyk-Krzeska
Maria F. Czyzyk-Krzeska
Supplementary Table S4 from Copper Drives Remodeling of Metabolic State and Progression of Clear Cell Renal Cell Carcinoma